Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Alternative Names: AAV-ZFP-VEGF; Ad-ZFP-VEGF; AdV-ZFP-VEGF; Tau-targeted ZFP-TFs - Sangamo Therapeutics; ZFP TF ATV; ZFP TF therapeutics - Sangamo

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo BioSciences; Sangamo Therapeutics
  • Class Gene therapies; Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators; Glial cell line-derived neurotrophic factor agonists; Nav1.8 voltage-gated sodium channel inhibitors; Neuron stimulants; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Age-related macular degeneration; Alzheimer's disease; Cancer; Neuropathic pain; Parkinson's disease

Highest Development Phases

  • Preclinical Alzheimer's disease
  • No development reported Neuropathic pain; Parkinson's disease
  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 29 Mar 2019 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Sangamo Therapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top